Low CCL19 expression is associated with adverse clinical outcomes for follicular lymphoma patients treated with chemoimmunotherapy

MLA

Zhishang Zhang, et al. “Low CCL19 Expression Is Associated with Adverse Clinical Outcomes for Follicular Lymphoma Patients Treated with Chemoimmunotherapy.” Journal of Translational Medicine, vol. 19, no. 1, Sept. 2021, pp. 1–13. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....68d3b15a447e630ec8d83b70a230d9b0&authtype=sso&custid=ns315887.

APA

Zhishang Zhang, Shasha Wang, Ning Lou, Jianliang Yang, Lin Gui, Yuankai Shi, Haizhu Chen, Yan Qin, Xiaohui He, Shengyu Zhou, Peng Liu, Xiaohong Han, Yu Zhou, Sheng Yang, Yunxia Tao, & Jiarui Yao. (2021). Low CCL19 expression is associated with adverse clinical outcomes for follicular lymphoma patients treated with chemoimmunotherapy. Journal of Translational Medicine, 19(1), 1–13.

Chicago

Zhishang Zhang, Shasha Wang, Ning Lou, Jianliang Yang, Lin Gui, Yuankai Shi, Haizhu Chen, et al. 2021. “Low CCL19 Expression Is Associated with Adverse Clinical Outcomes for Follicular Lymphoma Patients Treated with Chemoimmunotherapy.” Journal of Translational Medicine 19 (1): 1–13. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....68d3b15a447e630ec8d83b70a230d9b0&authtype=sso&custid=ns315887.